Evidence map›Paper›PMID 41535734›Full record

ArticleBMC immunology2026

Prognostic value of systemic immune-inflammation index to albumin ratio (SAR) for long-term all-cause mortality in sepsis survivors: evidence from a multicenter cohort with up to 6 years of follow-up.

Yanni Tan, Minghui Wu, Zhenwei Zhai, Quan Lu, Haolun Wang, Jingxia Sun, Qiu Wang, Junyu He, Jinming Yu, Jianhao Huang and 2 more

Abstract readMulticenter Study
In one paragraph

Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yanni Tan *Youjiang Medical University for Nationalities, Baise, Guangxi, 533000, People's Republic of China.
Minghui Wu *Department of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Zhenwei Zhai *Department of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Quan Lu *Department of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Haolun WangClinical Physician Training Base, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China.
Jingxia SunDepartment of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Qiu WangDepartment of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Junyu HeDepartment of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Jinming YuDepartment of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Jianhao HuangDepartment of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China.
Wenxin ChuDepartment of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China. chuwenxin_cwx@163.com.
Wensheng LuDepartment of Endocrinology and Metabolism, Guangxi Medical Sciences Academy & the People's Hospital of Guangxi Zhuang Autonomous Region, No. 6, Taoyuan Road, Nanning, Guangxi, 530021, People's Republic of China. Lwswxqz@163.com.ORCID 0000-0002-0212-3624

Funding

National Natural Science Foundation of China 82160052
6 · The paper itself

Abstract

objectivesPatients recovering from sepsis still face a higher long-term mortality risk. This study aims to explore the association between the systemic immune-inflammation index-to-albumin ratio (SAR) and the risk of long-term all-cause mortality (up to 6 years) in sepsis survivors.

methodsBetween January 2017 and December 2022, 461 participants with sepsis recurrence-free status for at least 3 months following the first-episode sepsis cure from Nanning Third People’s Hospital, Guangxi Medical Sciences Academy and the People’s Hospital of Guangxi Zhuang Autonomous Region, were enrolled. Participants were categorized into three groups based on SAR tertiles: low-level (< 32.15, n = 153), moderate-level (32.15–80.57, n = 154), and high-level (> 80.57, n = 154). All participants were followed up every 3 months for a median of 36 months up to 6 years. The relationships between SAR and all-cause mortality risk were analyzed.

resultsOf the 461 participants, 177 (38.4%) died. Multivariable Cox regression analysis showed that the high-level SAR group had a higher risk of all-cause mortality in model III (P = 0.014). Subgroup stratification analysis revealed that when grouped by SAR level tertiles (with the lowest tertile as the reference baseline for all-cause mortality, a hazard ratio (HR) = 1), each subsequent tertile increase in SAR level was associated with a 21.9% higher risk of all-cause mortality in patients aged ≥ 65 years (HR = 1.219, 95% CI = 0.954–1.558, P for interaction < 0.001), and a 26.1% higher risk in those with cardiovascular and cerebrovascular complications (HR = 1.261, 95% CI: 0.925–1.719, P for interaction < 0.001), respectively. Kaplan-Meier analysis indicated that higher SAR levels were associated with lower survival probability (log-rank, P = 0.00025). The restricted cubic spline (RCS) model identified an inverted J-shaped dose-dependent relationship between SAR level and all-cause mortality risk (P for overall < 0.0001). Receiver operating characteristic (ROC) analysis demonstrated an optimal SAR cutoff value of 113.561 for predicting all-cause mortality. Decision curve analysis (DCA) confirmed that SAR provided a greater net clinical benefit than existing indicators, such as the systemic immune-inflammation index (SII), red blood cell distribution width (RDW), and lymphocyte to high-density lipoprotein cholesterol ratio (LHR).

conclusionThe findings suggest that SAR may serve as a potential cofactor, alongside age and cardiovascular comorbidities, in clinical decision-making regarding long-term all-cause mortality risk in sepsis survivors.

Indexed as

InflammationSepsisSerum AlbuminAdultAgedBiomarkersFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisSurvivorsBiomarkersSerum AlbuminAll-cause mortalityPrognostic markerSepsisSystemic immune-inflammation index-to-albumin ratio

Identifiers

PMID41535734
PMCPMC12860170

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.